# VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML

> **NCT07407140** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 300 (estimated)

## Conditions studied

- AML, Adult

## Interventions

- **DRUG:** Gilteritinib + Azacitidine + Venetoclax
- **DRUG:** Cytarabine + Daunorubicin (or Idarubicin) + Gilteritinib
- **DRUG:** Re-induction Therapy
- **DRUG:** Consolidation Therapy
- **DRUG:** Maintenance Therapy

## Key facts

- **NCT ID:** NCT07407140
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-30
- **Primary completion:** 2029-02-01
- **Final completion:** 2030-12-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07407140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07407140, "VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07407140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*